Edesa Biotech, Inc. annual report, FY2016

Business context and reporting period

Entity mismatch: The request identifies Edesa Biotech, Inc., but the supplied Form 10-K is for Stellar Biotechnologies, Inc. This summary reflects the filing provided, not an Edesa filing. It covers the fiscal year ended September 30, 2016; quarterly figures include the three months ended September 30, 2016.

Stellar develops, manufactures and sells Keyhole Limpet Hemocyanin (KLH), an ingredient and immune-stimulating product used in drug development and immunodiagnostics. Its customers’ KLH-based drug candidates are still in development; the filing says none had reached commercial marketing.

Financial performance and liquidity

Fiscal 2016 fourth-quarter revenue was $277,000 and net loss was $1.349 million, versus $200,000 revenue and $1.538 million net loss in fiscal 2015’s fourth quarter. The filing does not state a gross margin figure.

At September 30, 2016, cash and cash equivalents were $7.417 million, short-term investments $3.989 million, working capital $11.476 million, and total assets $12.938 million. Current liabilities were $624,000; the balance sheet reports no debt or long-term obligations. Management said available resources were sufficient for planned operations for at least 12 months. The company reported no outstanding Canadian-dollar warrant liability at year-end.

Material changes versus the prior comparable period

• Revenue rose $513,000 (68%), chiefly from higher product sales as customer count and sales volume increased. Contract services revenue fell after a collaboration agreement concluded in December 2015.
• R&D expense increased to $1.729 million from $1.029 million, including work on aquaculture, the Mexico feasibility assessment, manufacturing and formulation.
• Net loss increased by about $2.2 million. Results included a $212,000 noncash warrant fair-value loss in 2016, compared with a $2.131 million noncash gain in 2015; foreign exchange also shifted from a $653,000 loss to a $77,000 gain.
• Cash and cash equivalents increased $3.461 million, while short-term investments declined $1.026 million. Financing activities provided $7.313 million, including a 2016 share offering and warrant exercises.
• Shares outstanding increased from 7.985 million to 10.136 million during the year. The July offering issued 1.688 million shares for $6.75 million gross proceeds and included warrants for up to 1.266 million additional shares at $4.50 each.

Outlook, commentary, risks and unusual items

Management expects continued losses and says future funding may be needed. The filing gives two different estimates for fiscal 2017 spending: approximately $6.0 million in the liquidity discussion and $6.5 million in a risk-factor discussion. It also describes current KLH capacity of about 1,500 grams annually and a potential increase to 20,000 grams over five to seven years, subject to funding and scale-up.

• Customer and development dependence: Demand depends on customer funding, clinical progress and regulatory approvals. Three customers accounted for 76% of FY2016 product and services revenue; one customer represented all year-end receivables.
• Concentrated operations and supply: Aquaculture, research and manufacturing were concentrated at the Port Hueneme site, with no active backup facility. Certain fill/finish and testing depend on third parties. A planned Baja California site remained under suitability assessment.
• Joint venture: Stellar owns 30% of Neostell with Neovacs and may have to provide additional pro-rata funding. The venture may be dissolved if specified milestones are not achieved by December 2017, absent other agreed action.
• Liquidity and dilution: Operating cash use remained substantial. Management had no committed future financing, and additional equity issuance could dilute shareholders. The filing notes an effective shelf registration statement.
• Other risks: KLH supply and production scale-up, competition, regulatory and environmental compliance, intellectual-property protection, foreign exchange exposure, and the potential impact of natural disasters at the single principal site.
• Unusual accounting item: Historical warrant fair-value gains and losses were noncash and driven by share-price changes; Canadian-dollar warrants were exercised or expired by December 2015.

The company reported effective disclosure controls and internal control over financial reporting as of September 30, 2016. Its auditor issued an unqualified opinion on the financial statements but did not audit internal control effectiveness. No material legal proceedings were reported.

Important facts for investors to verify

• Confirm the issuer: the supplied filing is Stellar Biotechnologies, Inc., not Edesa Biotech, Inc.
• Reconcile the conflicting fiscal 2017 spending estimates of $6.0 million and $6.5 million and assess runway against ongoing operating cash use.
• Review customer concentration, subsequent orders and receivable collections, given three-customer revenue concentration and one-customer receivables.
• Assess dilution from the 1.266 million warrants exercisable beginning January 6, 2017, the 2016 share offering, and any future shelf offerings.
• Track Neostell’s December 2017 milestones, funding obligations and the status and cost of the Mexico site assessment.
• Validate production capacity, scale-up funding needs, and the progress and regulatory outcomes of customers’ clinical programs.